Adaptin Bio, Inc.

Adaptin Bio, Inc. is a U.S.-based biotechnology company focused on developing APTN-101, a product candidate being advanced for glioblastoma multiforme (GBM). The company operates through a development-stage model that relies heavily on third-party vendors, consultants, and outsourced research and development support.

0.29

— Adaptin Bio, Inc.
	%
Drug candidate development	100% Development of APTN-101 through preclinical and clinical stages for GBM.
Licensing and IP support	0% Acquisition, licensing, and maintenance of biotechnology-related rights and patents.
Outsourced R&D operations	0% Management of third-party vendors, consultants, and service providers supporting development work.

Adaptin Bio does not currently sell approved products, so its direct customer base is not yet commercial...

Research and clinical service providersprimary
Third-party vendors and consultants that perform preclinical, clinical, regulatory, and administrative work for APTN-101.
Potential collaboration partnerssecondary
Biopharma partners that may license, co-develop, or help commercialize product candidates.
Future oncology treatment providersemerging
Hospitals and physicians that would use an approved GBM therapy if development succeeds.

Adaptin Bio is incorporated in Delaware and is based in the United States, where its corporate, financing, and...

•Incorporated in Delaware, United States
•Corporate and financing activities are U.S.-centered
•Development work is outsourced rather than tied to owned plants
•Future clinical and regulatory activity will be shaped by U.S. oversight

The company’s strategy is centered on advancing APTN-101 through preclinical and clinical development and ultimately...

Advance APTN-101 in GBMshort-term

The company’s value creation depends on moving its lead candidate through development and toward approval.

Secure external fundingshort-term

Development-stage biotech programs require capital before product revenue can be generated.

Build a commercialization pathmedium-term

Regulatory approval and eventual market access are required before the company can monetize its pipeline.

Adaptin Bio faces the classic risks of a development-stage biotechnology company: clinical failure, regulatory delay,...

critical

Clinical development failure

The company’s lead asset is still in development and may not demonstrate safety or efficacy.

Scope: APTN-101 for GBM
Materiality: high

high

Funding shortfall and dilution

Operations are expected to be financed through external capital until product revenue exists.

Scope: Equity and debt financing needs
Materiality: high

high

Regulatory and approval risk

Biotech commercialization depends on successful clinical trials and regulatory clearance.

Scope: FDA and related approval processes
Materiality: high

medium

Vendor and outsourcing execution risk

The company relies on third parties for much of its development work and expense forecasting.

Scope: Third-party service providers and consultants
Materiality: medium

medium

Intellectual property risk

Patent prosecution, maintenance, and defense can be costly and uncertain in biotech.

Scope: Patent applications and IP claims
Materiality: medium

Derivative liabilities

Reported earnings and balance sheet volatility

Accrued research and development liabilities

Expense timing and liability estimates

Stock-based compensation

Non-cash compensation expense

Going-concern assessment

Liquidity disclosure and financial statement presentation

Adaptin Bio, Inc.

Clinical development failure

Funding shortfall and dilution

Regulatory and approval risk

Vendor and outsourcing execution risk

Intellectual property risk

BIOADAPTIVES, INC.

AdaptHealth Corp.

DYADIC INTERNATIONAL INC

Aptevo Therapeutics Inc.

ANAPTYSBIO, INC

Adapti, Inc.